<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01299103</url>
  </required_header>
  <id_info>
    <org_study_id>PEL-10-02</org_study_id>
    <nct_id>NCT01299103</nct_id>
  </id_info>
  <brief_title>Safety and Efficacy of Single Therapy Versus Double and Triple Therapy of the Pellevé™ Wrinkle Treatment System for the Treatment of Moderate Facial Wrinkles</brief_title>
  <official_title>A Prospective, Randomized, Open-Label, 3-Arm Parallel Study Comparing the Safety and Efficacy of Single Therapy Versus Double and Triple Therapy Using the Surgitron® Dual RF™ S5 With the Pellevé™ Wrinkle Treatment Handpiece and Pellevé™ Treatment Gel for the Treatment of Moderate Facial Wrinkles in Fitzpatrick Skin Types I - IV</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Ellman International</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Ellman International</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The study will enroll and treat a patients to assess improvement in the appearance of facial
      wrinkles.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The study will enroll and treat a total of 44 subjects (23 in treatment Group A receiving a
      single treatment and 21 in treatment Group B receiving two treatments) with moderate facial
      wrinkles corresponding to a grade of 4-6 on the validated Fitzpatrick Wrinkle Assessment
      Scale.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>April 2010</start_date>
  <completion_date type="Actual">April 2012</completion_date>
  <primary_completion_date type="Actual">April 2012</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Fitzpatrick Wrinkle Assessment</measure>
    <time_frame>change in Fitzpatrick Wrinkle Score between baseline and 90 days post treatment assessment.</time_frame>
    <description>Subject photos will be evaluated using the 9-point Fitzpatrick Wrinkle Assessment Scale at all follow up visits. An improvement is noted by a decrease in the numeric Fitzpatrick Wrinkle score. The Fitzpatrick Wrinkle Assessment ranges from 1-9. Wrinkle Score between baseline and 90 days post treatment assessment. Positive values indicates an increase in score, while negative values indicate a decrease</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Adverse Events</measure>
    <time_frame>90 days post treatment</time_frame>
    <description>The rate of adverse events occurring in treatment subjects will be assessed.</description>
  </primary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">40</enrollment>
  <condition>Appearance of Facial Wrinkles</condition>
  <arm_group>
    <arm_group_label>Single Treatment</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Treatment of facial wrinkle with one treatment only</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Double Treatment</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Treatment of facial wrinkle with two treatments</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Triple treatment</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Treatment of facial wrinkle with three treatments</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Pelleve Wrinkle Treatment System</intervention_name>
    <description>comparison of single vs. double and triple treatment with the Pelleve Wrinkle Treatment System</description>
    <arm_group_label>Single Treatment</arm_group_label>
    <arm_group_label>Double Treatment</arm_group_label>
    <arm_group_label>Triple treatment</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Females 35-60 years of age with Fitzpatrick Skin Color Type I-IV.

          -  Subjects with clinical evidence of facial wrinkles mild to moderate in severity as
             specified by a grade 4-6 on the Fitzpatrick Wrinkle Assessment Scale.

          -  Willingness and ability to comply with protocol requirements, including returning for
             follow-up visits and abstaining from exclusionary procedures for the duration of the
             study.

          -  Willingness and ability to provide written photo consent and adherence to photography
             procedures (i.e., removal of jewelry and makeup).

          -  Willingness and ability to provide written informed consent prior to performance of
             any study related procedure.

        Exclusion Criteria:

          -  Subjects who are pregnant, nursing, planning to become pregnant, and/or not using a
             reliable form of birth control.

          -  Subjects who have had prior exposure to any hyaluronic acid, or any other filler,
             injection for any purpose in the 12 months preceding study enrollment through the
             duration of the study.

          -  Subjects who have had prior exposure to any botulinum toxin for facial rhytids in the
             6 months preceding study enrollment through the duration of the study.

          -  Subjects who have had a prior cosmetic procedure to improve facial rhytids (i.e.,
             rhytidectomy, periorbital or eyelid/eyebrow surgery, brow lift, CO2/erbium laser
             resurfacing, Thermage/Thermacool radiofrequency treatment) within 12 months or who
             have visible scars that may affect evaluation of response and/or quality of
             photography.

          -  Ablative skin resurfacing on the glabellar area within the previous 6 months or during
             the study.

          -  Retinoid, microdermabrasion, or prescription level glycolic acid treatments within 3
             months prior to study participation or during the study.

          -  Active cut, wound, or infection on the skin.

          -  Oral Isotretinon within the past 12 months.

          -  Active HSV-1.

          -  History of keloids or hypertrophic scarring.

          -  Existing or history of skin malignancy.

          -  Any existing skin disease.

          -  History of collagen or vascular disease.

          -  Subjects who have implantable pacemaker, automatic implantable defibrillator/
             cadioversor (AICD), or any other implantable electric device.

          -  Subjects who have used, within 30 days, any medication that can cause dermal
             hypersensitivity or affect skin characteristics.

          -  History of autoimmune disease.

          -  History of any disease that inhibits pain sensation.

          -  History of Diabetes I or II.

          -  Concurrent therapy that, in the investigator's opinion, would interfere with the
             evaluation of the safety or efficacy of the study medication.

          -  Subjects who anticipate the need for surgery or overnight hospitalization during the
             study.

          -  Subjects who, in the Investigator's opinion, have a history of poor cooperation,
             non¬compliance with medical treatment or unreliability.

          -  Enrollment in any active study involving the use of investigational devices or drugs.
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>35 Years</minimum_age>
    <maximum_age>60 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Steven H. Dayan, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>DeNova Research</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>DeNova Research Institute</name>
      <address>
        <city>Chichago</city>
        <state>Illinois</state>
        <zip>60611</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>March 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 4, 2011</study_first_submitted>
  <study_first_submitted_qc>February 16, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 18, 2011</study_first_posted>
  <results_first_submitted>November 10, 2014</results_first_submitted>
  <results_first_submitted_qc>March 28, 2016</results_first_submitted_qc>
  <results_first_posted type="Estimate">April 15, 2016</results_first_posted>
  <last_update_submitted>March 28, 2016</last_update_submitted>
  <last_update_submitted_qc>March 28, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">April 15, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>wrinkle</keyword>
  <keyword>rhytide</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Facies</mesh_term>
  </condition_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Single Treatment</title>
          <description>Subjects receive one treatment</description>
        </group>
        <group group_id="P2">
          <title>Double Treatment</title>
          <description>Subjects receive two treatments</description>
        </group>
        <group group_id="P3">
          <title>Triple Treatment</title>
          <description>Subjects receive three treatments</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="15"/>
                <participants group_id="P2" count="15"/>
                <participants group_id="P3" count="10"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="15"/>
                <participants group_id="P2" count="13"/>
                <participants group_id="P3" count="8"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="2"/>
                <participants group_id="P3" count="2"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Single Treatment</title>
          <description>Pelleve Wrinkle Treatment System: comparison of single vs. double and triple treatment with the Pelleve Wrinkle Treatment System</description>
        </group>
        <group group_id="B2">
          <title>Double Treatment</title>
          <description>Pelleve Wrinkle Treatment System: comparison of single vs. double and triple treatment with the Pelleve Wrinkle Treatment System</description>
        </group>
        <group group_id="B3">
          <title>Triple Treatment</title>
          <description>Pelleve Wrinkle Treatment System: comparison of single vs. double and triple treatment with the Pelleve Wrinkle Treatment System</description>
        </group>
        <group group_id="B4">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="15"/>
            <count group_id="B2" value="15"/>
            <count group_id="B3" value="10"/>
            <count group_id="B4" value="40"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="52" spread="7.2"/>
                    <measurement group_id="B2" value="52" spread="6.5"/>
                    <measurement group_id="B3" value="53" spread="5.2"/>
                    <measurement group_id="B4" value="52" spread="6.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>&lt;=18 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Between 18 and 65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="15"/>
                    <measurement group_id="B2" value="15"/>
                    <measurement group_id="B3" value="10"/>
                    <measurement group_id="B4" value="40"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;=65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="15"/>
                    <measurement group_id="B2" value="15"/>
                    <measurement group_id="B3" value="10"/>
                    <measurement group_id="B4" value="40"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="15"/>
                    <measurement group_id="B2" value="15"/>
                    <measurement group_id="B3" value="10"/>
                    <measurement group_id="B4" value="40"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Fitzpatrick Wrinkle Assessment</title>
        <description>Subject photos will be evaluated using the 9-point Fitzpatrick Wrinkle Assessment Scale at all follow up visits. An improvement is noted by a decrease in the numeric Fitzpatrick Wrinkle score. The Fitzpatrick Wrinkle Assessment ranges from 1-9. Wrinkle Score between baseline and 90 days post treatment assessment. Positive values indicates an increase in score, while negative values indicate a decrease</description>
        <time_frame>change in Fitzpatrick Wrinkle Score between baseline and 90 days post treatment assessment.</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Single Treatment</title>
            <description>Subjects receive one treatment</description>
          </group>
          <group group_id="O2">
            <title>Double Treatment</title>
            <description>Subjects receive two treatments</description>
          </group>
          <group group_id="O3">
            <title>Triple Treatment</title>
            <description>Subjects receive three treatments</description>
          </group>
        </group_list>
        <measure>
          <title>Fitzpatrick Wrinkle Assessment</title>
          <description>Subject photos will be evaluated using the 9-point Fitzpatrick Wrinkle Assessment Scale at all follow up visits. An improvement is noted by a decrease in the numeric Fitzpatrick Wrinkle score. The Fitzpatrick Wrinkle Assessment ranges from 1-9. Wrinkle Score between baseline and 90 days post treatment assessment. Positive values indicates an increase in score, while negative values indicate a decrease</description>
          <units>units on a scale, change in Fitzpatrick</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="15"/>
                <count group_id="O2" value="13"/>
                <count group_id="O3" value="8"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.0" spread="0.98"/>
                    <measurement group_id="O2" value="1.5" spread="1.9"/>
                    <measurement group_id="O3" value="1.1" spread="1.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Adverse Events</title>
        <description>The rate of adverse events occurring in treatment subjects will be assessed.</description>
        <time_frame>90 days post treatment</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Single Treatment</title>
            <description>Subjects receive one treatment</description>
          </group>
          <group group_id="O2">
            <title>Double Treatment</title>
            <description>Subjects receive two treatments</description>
          </group>
          <group group_id="O3">
            <title>Triple Treatment</title>
            <description>Subjects receive three treatments</description>
          </group>
        </group_list>
        <measure>
          <title>Adverse Events</title>
          <description>The rate of adverse events occurring in treatment subjects will be assessed.</description>
          <units>number of adverse events reported</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="15"/>
                <count group_id="O2" value="13"/>
                <count group_id="O3" value="8"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Single Treatment</title>
          <description>Subjects receive one treatment</description>
        </group>
        <group group_id="E2">
          <title>Double Treatment</title>
          <description>Subjects receive two treatments</description>
        </group>
        <group group_id="E3">
          <title>Triple Treatment</title>
          <description>Subjects receive three treatments</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="10"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="10"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Dr. Steven Dayan</name_or_title>
      <organization>Chicago Center for Facial Plastic Surgery</organization>
      <phone>(312) 335-2070</phone>
      <email>sdayan@drdayan.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

